In Brazil, Huna’s deployments have screened more than 500,000 people and detected hundreds of cancer cases. Its experience also highlights a critical ‘last mile’: identifying risk is not enough if a person does not complete the diagnostic pathway. Recognition and funding from the Challenge could help support further validation across new populations and facilitate new international partnerships.
Innovation is only the starting point
Together, these solutions show that useful signals can come from a variety of sources – including clinical encounters, environmental surveillance, and routine diagnostics. They also show that anticipatory approaches can be built where connectivity, specialist capacity, or access to screening is limited, and that innovation developed in those settings can share insights that can be localised and adopted globally.
But a successful technology or pilot is not the same as system-wide impact. Scaling requires local validation, integrated into existing workflows, responsible data governance, sustainable financing, workforce training, and evidence that earlier insight changes decisions and outcomes.
A successful technology or pilot is not the same as system-wide impact.
“The solutions emerging from this Challenge reflect both the urgency and the opportunity facing health systems globally. By bringing innovators together with policymakers, funders and implementers through platforms such as Future Health, we can help accelerate solutions that are locally grounded and capable of delivering impact at scale,” said Hala Hanna, Executive Director of MIT Solve.
From recognition to system-level impact